• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Shanks Virginia E was granted 2,571 shares, increasing direct ownership by 6% to 48,900 units (SEC Form 4)

    5/18/26 2:31:10 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SHANKS VIRGINIA E

    (Last)(First)(Middle)
    6601 W BROAD ST

    (Street)
    RICHMOND VIRGINIA 23230

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    ALTRIA GROUP, INC. [ MO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/14/2026A2,571(1)A$048,900(2)D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Deferred stock awarded under the 2025 Stock Compensation Plan for Non-Employee Directors.
    2. Includes 19,936 deferred shares held in the Stock Compensation Plan for Non-Employee Directors, including an increase of 1,113 shares acquired through the reinvestment of dividends on deferred shares since May 15, 2025, the date of the last reportable transaction. Also includes 1,857 shares acquired through the reinvestment of dividends on shares held in an investment account since May 15, 2025, the date of the last reportable transaction.
    Remarks:
    Mary C. Bigelow for Virginia E. Shanks05/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $MO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    1/9/2026$63.00Neutral → Buy
    UBS
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    More analyst ratings

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    SEC Filings

    View All

    SEC Form SD filed by Altria Group Inc.

    SD - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/28/26 11:07:45 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 10-K/A filed by Altria Group Inc.

    10-K/A - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/27/26 2:42:37 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    5/18/26 4:42:27 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Smokeless Tobacco Company Announces Plan to Modernize Manufacturing Footprint Through Facility Relocation

    U.S. Smokeless Tobacco Company LLC (USSTC), a subsidiary of Altria Group, Inc. (NYSE:MO), today announced plans to consolidate certain operations as part of a long-term strategy to modernize its manufacturing footprint and drive operational efficiencies. USSTC will transition manufacturing operations from its Nashville, Tennessee plant to a new facility to be constructed on an existing campus in Hopkinsville, Kentucky. Production in Nashville will wind down gradually, with operations expected to conclude in early 2028. This phased approach is designed to support continuity of operations and a smooth transition for employees. "Modernizing our manufacturing capabilities is essential to po

    5/21/26 4:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Holds 2026 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2026 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer (CEO), addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Appointment of CEO Following today's Annual Meeting, Sal Mancuso succeeded Billy Gifford as Altria's CEO. At the end of 2025, Billy Gifford announced his decision to retire after more than 30 years of distinguished service with the Altria family of companies. "Sal is immensely qualified to lead Altria, having served in numerous leadership positions during his more than 30-y

    5/14/26 2:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria to Host Webcast of 2026 Annual Meeting of Shareholders

    Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2026 Annual Meeting of Shareholders ("2026 Annual Meeting" or "meeting") on Thursday, May 14, 2026 at 9:00 a.m. Eastern Time. The 2026 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2026 Annual Meeting record date (March 25, 2026) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2026 Proxy Statement. If you are not a sharehold

    5/1/26 10:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kelly Ennis Debra J sold $418,318 worth of shares (5,790 units at $72.25), decreasing direct ownership by 7% to 73,809 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/28/26 2:31:24 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R sold $145,118 worth of shares (2,000 units at $72.56), decreasing direct ownership by 7% to 25,102 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/28/26 2:31:18 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Strahlman Ellen R was granted 2,571 shares, increasing direct ownership by 10% to 27,102 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    5/18/26 2:31:49 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Neutral to Buy and set a new price target of $63.00

    1/9/26 8:23:08 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Holds 2026 Annual Meeting of Shareholders; Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (Altria) (NYSE:MO) held our 2026 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria's Chief Executive Officer (CEO), addressed shareholder questions. A copy of the presentation and a replay of the webcast are available on www.altria.com. Appointment of CEO Following today's Annual Meeting, Sal Mancuso succeeded Billy Gifford as Altria's CEO. At the end of 2025, Billy Gifford announced his decision to retire after more than 30 years of distinguished service with the Altria family of companies. "Sal is immensely qualified to lead Altria, having served in numerous leadership positions during his more than 30-y

    5/14/26 2:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director George Muñoz from Board of Directors

    Altria Group, Inc. (Altria) (NYSE:MO) -- George Muñoz, a director of Altria since 2004, notified Altria of his decision to retire from service on our Board of Directors (Board) following the completion of his current term. Consequently, Mr. Muñoz will not stand for re-election to our Board at our 2026 Annual Meeting of Shareholders, which Altria anticipates holding on May 14, 2026. "George has made extensive and significant contributions to Altria over more than 20 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank George for his long-standing and valuable service and wish him the very best upon his retirement." Mr. Muñoz is Chair of the Compensation and Ta

    10/9/25 8:35:00 AM ET
    $LAUR
    $MO
    Other Consumer Services
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Reports 2026 First-Quarter Results; Reaffirms Full-Year Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2026 first-quarter business results and reaffirms our guidance for 2026 full-year adjusted diluted earnings per share (EPS). "We delivered a strong start to the year, growing adjusted diluted EPS by 7.3% in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "Our highly cash-generative businesses supported significant returns to shareholders through dividends and share repurchases, while we continued to invest in support of our Vision." "Our smokeable products segment generated strong income growth. Marlboro strengthened its position in the premium segment, and PM USA continued to execute its total portfolio strategy w

    4/30/26 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on April 30, 2026 to shareholders of record as of March 25, 2026. The ex-dividend date is March 25, 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260225648687/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    2/26/26 1:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 Fourth-Quarter and Full-Year Results; Provides 2026 Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 fourth-quarter and full-year business results and provides our guidance for 2026 full-year adjusted diluted earnings per share (EPS). "2025 was a year of continued momentum for Altria, marked by strong financial performance, strategic progress across our smoke-free portfolio, new relationships in support of our long-term growth goals and significant cash returns to shareholders," said Billy Gifford, Altria's Chief Executive Officer. "For the full year, we grew adjusted diluted earnings per share by 4.4% and returned $8 billion to shareholders through dividends and share repurchases combined." "We expect to deliver 2026 full-year adjust

    1/29/26 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care